Vancomycin

Vancomycin

• CAS Number: 1404-90-6
• UNSPSC Description: Vancomycin is an antibiotic for the treatment of bacterial infections.
• Target Antigen: Antibiotic; Autophagy; Bacterial
• Type: Natural Products
• Related Pathways: Anti-infection;Autophagy
• Applications: COVID-19-immunoregulation
• Field of Research: Infection; Cancer
• Assay Protocol: https://www.medchemexpress.com/vancomycin.html
• Purity: 99.39
• Solubility: DMSO : 125 mg/mL (ultrasonic;warming;heat to 60°C)
• Smiles: O[C@@H]1[C@@H](O[C@@](O[C@@H](C)[C@H]2O)([H])C[C@@]2(N)C)[C@@H](O[C@H](CO)[C@H]1O)OC3=C(OC4=CC=C([C@H]([C@H]5NC([C@H](NC)CC(C)C)=O)O)C=C4Cl)C=C([C@](NC([C@@H](NC5=O)CC(N)=O)=O)([H])C(N[C@](C6=O)([H])C7=CC8=C(O)C=C7)=O)C=C3OC9=CC=C([C@H]([C@](C(N[C@@](C(O)=O)([H])C%10=C8C(O)=CC(O)=C%10)=O)([H])N6)O)C=C9Cl
• Molecular Weight: 1449.25
• References & Citations: [1]Rybak MJ, et al. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S35-9.|[2]Watanakunakorn C, et al. Mode of action and in-vitro activity of vancomycin. J Antimicrob Chemother. 1984 Dec;14 Suppl D:7-18.|[3]Warren CA, et al. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice. Antimicrob Agents Chemother. 2013 Feb;57(2):689-96.|[4]Juan He, et al. Vitamin C reduces vancomycin-related nephrotoxicity through the inhibition of oxidative stress, apoptosis, and inflammation in mice. Ann Transl Med. 2021 Aug; 9(16): 1319.|[5]Ping Yu, et al. N-acetylcysteine Ameliorates Vancomycin-induced Nephrotoxicity by Inhibiting Oxidative Stress and Apoptosis in the in vivo and in vitro Models. Int J Med Sci. 2022; 19(4): 740–752.ACS Infect Dis. 2021 Aug 4.|ACS Infect Dis. 2023 Nov 28.|ACS Infect Dis. 2024 Apr 12;10(4):1327-1338.|ACS Infect Dis. 2024 Jul 27.|ACS Omega. 2023 Feb 2; 8 (6), 5415-5425.|ACS Omega. 2023 Mar 6.|ACS Omega. March 3, 2022.|Adv Funct Mater. 2024 Jun 19.|Am J Chin Med. 2024 Aug 21:1-28.|Appl Microbiol Biotechnol. 2022 Apr;106(7):2689-2702.|Aquaculture. 2021, 736248.|Biochem Pharmacol. 2024 Oct 23:116593.|bioRxiv. 2024 May 10.|Cancer Immunol Res. 2022 Dec 2;10(12):1542-1558.|Cell Death Dis. 2021 Jun 7;12(6):582.|Cell Metab. 2023 Sep 29:S1550-4131(23)00340-6.|Cell Metab. 2024 Sep 28:S1550-4131(24)00366-8.|Chemosphere. 2019 Jun;225:378-387. |Curr Microbiol. 2023 May 31;80(7):230.|Emerg Microbes Infect. 2022 Feb 22;1-34.|Emerg Microbes Infect. 2024 Dec;13(1):2321981.|Environ Health Perspect. 2022 Jun;130(6):67009.|Front Microbiol. 2020 Jul 31;11:1720.|Genome Biol. 2023 Apr 30;24(1):98.|Gut Microbes. 2023 Dec;15(2):2249143.|Heliyon. 2024 Jan 4.|Infect Drug Resist. 2021 Dec 16;14:5449-5456.|Int J Biol Macromol. 2024 Sep 19:135835.|Int J Med Microbiol. 2020 Jan;69(1):120-131.|Int J Med Sci. 2022 Apr 11;19(4):740-752.|iScience. 2023 Mar.|iScience. 2023 Oct 5.|iScience. 5 January 2022, 103731.|J Agric Food Chem. 2024 Apr 10.|J Appl Microbiol. 2024 Jan 4:lxae001.|J Cell Physiol. 2021 Dec 8.|J Pharm Anal. 2023 Jun 16.|Life Sci. 2020 Nov 15;261:118473.|Microb Biotechnol. 2021 Mar 15.|Microbiol Spectr. 2022 Mar 2;e0054121.|Mol Immunol. 2022 Jul 6;149:94-106.|Mol Pharm. 2022 Oct 21.|Naunyn Schmiedebergs Arch Pharmacol. 2024 Oct 1.|Neural Regen Res. 2024 Sep 1;19(9):2081-2088.|Pharmacol Res. 2024 May 21:205:107229.|Res Sq. 2024 Oct 02.|Research Square Preprint. 2020 Jun.|Transl Res. 2022 Sep 5;S1931-5244(22)00198-0.|Virulence. 2024 Dec;15(1):2367659.|Virulence. 2024 Oct 10:2415952.|Chem Eng J. 2024 Apr 15, 486 150125.|Front Aging Neurosci. 2022 Jul 28;14:858130.|NPJ Biofilms Microbiomes. 2024 Oct 28;10(1):111.|Pol J Microbiol. 2023 Jun 14;72(2):199-208.|Redox Biol. 2023 Oct 10, 102929.|Small. 2021 Dec 19;e2107137.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
• Clinical Information: Launched